🔗 Permalink

Inventor profile of:

Michael E. Bozik

City:

Pittsburgh, Pennsylvania

Country:

United States

Published Applications:

Last publication date:

2025-03-27

Top Assignees for applications by Michael E. Bozik

The entities that hold a legal rights for patent applications filed by inventor Bozik Michael E.:

KNOPP BIOSCIENCES, LLC 15 Pittsburgh, PA United States
Knopp Neurosciences Inc. 12 Pittsburgh, PA United States
Areteia Therapeutics, Inc. 3 Chapel Hill, NC United States
Knopp Biosciences LLC 1 Pittsburg, PA United States
Biohaven Therapeutics Ltd. 1 Tortola, Virgin Islands (British)

Recent patent applications by Bozik Michael E.

Michael E. Bozik from Pittsburgh, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-03-27

US20250099437A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ELEVATED LEVELS OF EOSINOPHILS AND/OR BASOPHILS

#2 | 2023-09-07

US20230277509A1

Human necessities

Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils

#3 | 2022-10-13

US20220323417A1

Human necessities

METHODS OF USE FOR KV7 CHANNEL ACTIVATORS

#4 | 2021-09-02

US20210267949A1

Human necessities

Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils

#5 | 2019-10-24

US20190321339A1

Human necessities

Compositions and methods for treating conditions related to increased eosinophils

#6 | 2019-01-24

US20190022070A1

Human necessities

Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders

#7 | 2018-09-27

US20180271840A1

Human necessities

Compositions and methods for treating amyotrophic lateral sclerosis in responders

#8 | 2018-09-27

US20180271839A1

Human necessities

Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils

#9 | 2018-08-16

US20180228777A1

Human necessities

Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils

#10 | 2018-04-26

US20180110758A1

Human necessities

COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE

#11 | 2018-01-18

US20180015073A1

Human necessities

Compositions and methods for treating chronic urticaria

#12 | 2017-10-05

US20170281605A1

Human necessities

Compositions and methods for treating amyotrophic lateral sclerosis in responders

#13 | 2017-10-05

US20170281604A1

Human necessities

Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders

#14 | 2016-12-08

US20160354350A1

Human necessities

Compositions and methods for treating conditions related to increased eosinophils

#15 | 2016-07-07

US20160193187A1

Human necessities

Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders

#16 | 2016-07-07

US20160193186A1

Human necessities

Compositions and methods for treating chronic urticaria

#17 | 2016-06-09

US20160158205A1

Human necessities

Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils

#18 | 2016-02-04

US20160030397A1

Human necessities

Compositions and methods of using (R)-pramipexole

#19 | 2016-01-28

US20160022647A1

Human necessities

COMPOSITIONS AND METHODS OF USING R(+) PRAMIPEXOLE

#20 | 2015-01-15

US20150018397A1

Human necessities

Compositions and methods for treating conditions related to increased eosinophils

#21 | 2014-11-06

US20140329869A1

Human necessities

Compositions and methods for treating amyotrophic lateral sclerosis in responders

#22 | 2014-01-30

US20140031401A1

Human necessities

Modified Release Formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and Methods of Using the Same

#23 | 2013-11-21

US20130310430A1

Human necessities

COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE

#24 | 2013-09-19

US20130245081A1

Human necessities

Compositions and Methods for Treating Amyotrophic Lateral Sclerosis

#25 | 2013-09-05

US20130230569A1

Human necessities

COMPOSITIONS OF R(+) AND S(-) PRAMIPEXOLE AND METHODS OF USING THE SAME

#26 | 2013-05-16

US20130123312A1

Human necessities

Compositions and Methods of Using R(+) Pramipexole

#27 | 2012-09-06

US20120225915A1

Human necessities

Compositions and Methods of Using R(+) Pramipexole

#28 | 2011-12-01

US20110293718A1

Human necessities

Compositions of R(+) and S(−) pramipexole and methods of using the same

#29 | 2011-09-15

US20110224268A1

Human necessities

Compositions and methods of using R(+) pramipexole

#30 | 2011-08-04

US20110190356A1

Human necessities

Compositions and Methods of Using (R)- Pramipexole

#31 | 2011-01-13

US20110009460A1

Human necessities

COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS

#32 | 2009-02-26

US20090054504A1

Human necessities

Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same

#33 | 2009-02-12

US20090042956A1

Human necessities

Compositions and methods of using (R)-pramipexole

#34 | 2008-01-17

US20080014259A1

Human necessities

Compositions of R(+) and S(−) pramipexole and methods of using the same

#35 | 2007-11-08

US20070259930A1

Human necessities

COMPOSITIONS AND METHODS OF USING R(+) PRAMIPEXOLE

InventorID:

249367 ⎘